MétaCan
Menu
Back to cohort

The Financial Burden of Prescription Medications in Chronic Obstructive Pulmonary Disease

2025· article· en· W4410272711 on OpenAlexaffabout
Joseph Emil Amegadzie, Jeenat Mehareen, Mohsen Sadatsafavi

Bibliographic record

VenueAmerican Journal of Respiratory and Critical Care Medicine · 2025
Typearticle
Languageen
FieldHealth Professions
TopicGlobal Health Care Issues
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsMedicinePulmonary diseaseMedical prescriptionIntensive care medicineInternal medicinePharmacology

Abstract

fetched live from OpenAlex

Abstract RATIONALE: Medication costs are an important component of burden in many chronic conditions, and in many health jurisdictions, including in Canada, patients are at least partially responsible for covering their costs. We examined the excess medication costs, and the share of out-of-pocket costs, in individuals with chronic obstructive pulmonary disease (COPD). METHODS: Using administrative health databases of British Columbia, Canada, from 2001 to2020, we created a retrospective cohort of physician-diagnosed COPD patients ≥45 years of age.We constructed a comparison cohort from the general population, matching on key demographic and socioeconomic variables such as sex, year of birth, health service region, and neighbourhood income. Direct medical costs were assessed by analyzing detailed billing records from thePharmaNET medication dispensation dataset. Using generalized linear models combined with generalized estimating equations, we estimated the excess direct medication costs as the difference in all-cause medication costs between the COPD and non-COPD cohorts. These excess costs were calculated by comparing the overall medical expenses between individuals with COPD and those in the control cohort. Costs were reported in 2020 Canadian dollars ($). RESULTS: The final sample consisted of 207,502 COPD and 403,941 non-COPD individuals, with a mean baseline age of 68.7 for COPD, of whom 52.4% were male. The estimated average excess medication costs amounted to $1336 per patient-year (PY) [95% confidence interval (CI):$1,321-$1,352], with out-of-pocket expenses contributing $528/PY (95% CI: $521-$535). From2001 to 2020, the Average Annual Percentage Change (AAPC) for out-of-pocket costs was 10%, significantly higher than the overall medication cost increase (AAPC=6%). In both males and females, younger adults (aged 45-64 years) bore a higher financial burden compared to older adults (>=65 years). A similar trend was observed in males, with younger men incurring $485versus $473 for older men. Strikingly, out-of-pocket COPD-related medication costs represented50% of the total COPD-related medication cost. CONCLUSION: COPD represents a major financial burden for healthcare payers and individuals aged 45 and older in Canada. This study reveals that while more than half of the prescription drug costs were covered by traditional plans, patients were still responsible for 40%of out-of-pocket expenses. These findings emphasize the growing financial strain faced by patients managing COPD, underscoring the escalating personal costs associated with the condition.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.010
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.300
Threshold uncertainty score0.597

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.010
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.003
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.418
Teacher spread0.396 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueAmerican Journal of Respiratory and Critical Care MedicineSame topicGlobal Health Care IssuesFrench-language works237,207